Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Short term Debt (2020 - 2025)

Historic Short term Debt for Eton Pharmaceuticals (ETON) over the last 6 years, with Q3 2025 value amounting to $2.8 million.

  • Eton Pharmaceuticals' Short term Debt fell 3270.3% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 3270.3%. This contributed to the annual value of $5.4 million for FY2023, which is 42081.32% up from last year.
  • Latest data reveals that Eton Pharmaceuticals reported Short term Debt of $2.8 million as of Q3 2025, which was down 3270.3% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Short term Debt ranged from a high of $5.4 million in Q4 2023 and a low of $364000.0 during Q2 2022
  • For the 5-year period, Eton Pharmaceuticals' Short term Debt averaged around $2.2 million, with its median value being $1.5 million (2021).
  • As far as peak fluctuations go, Eton Pharmaceuticals' Short term Debt tumbled by 5140.19% in 2022, and later surged by 42081.32% in 2023.
  • Eton Pharmaceuticals' Short term Debt (Quarter) stood at $1.4 million in 2021, then decreased by 27.15% to $1.0 million in 2022, then soared by 420.81% to $5.4 million in 2023, then dropped by 23.33% to $4.1 million in 2024, then plummeted by 32.7% to $2.8 million in 2025.
  • Its Short term Debt stands at $2.8 million for Q3 2025, versus $2.8 million for Q2 2025 and $4.1 million for Q3 2024.